VistaGen Therapeutics Inc.
09/11/2026 | Press release | Distributed by Public on 09/11/2026 04:02
Proxy Results (Form 8-K)
Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 10, 2026, Vistagen Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting"). At the 2026 Annual Meeting, as set forth below, the Company's stockholders: (i) elected each of the four director nominees to the Company's Board of Directors (the "Board"); (ii) approved, on an advisory basis, the compensation paid to the Company's named executive officers; and (iii) ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending March 31, 2027.
The matters voted upon at the 2026 Annual Meeting and the results of the voting by the Company's stockholders are as follows:
Proposal No. 1 - Election of Directors
| For | Withheld | ||||||||||
|
Jon S. Saxe, J.D., LL.M.
Chair and Independent Director
|
7,354,923 | 1,141,965 | |||||||||
|
Ann M. Cunningham, MBA
Independent Director
|
4,664,450 | 3,832,438 | |||||||||
|
Douglas J. Williamson, M.D.
Independent Director
|
7,382,907 | 1,113,981 | |||||||||
|
Shawn K. Singh, J.D.
President, Chief Executive Officer and Director
|
4,971,180 | 3,525,708 | |||||||||
Members of the Board are elected by a plurality of the votes cast. Accordingly, each of the director nominees named above was elected to serve on the Board until the Company's 2027 Annual Meeting of Stockholders, or until her or his successor is elected and qualified.
Proposal No. 2 - Non-Binding Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal)
| For | Against | Abstain | ||||||||||||
| Votes | 6,625,045 | 1,142,430 | 729,413 | |||||||||||
The vote required to approve the non-binding advisory vote on executive compensation paid to the Company's named executive officers was the affirmative vote of a majority of the votes cast on the proposal. Accordingly, the Company's stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, as reported in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on July 31, 2026.
Proposal No. 3 - Ratification of Appointment of Independent Auditors
| For | Against | Abstain | ||||||||||||
| Votes | 22,495,649 | 680,897 | 685,683 | |||||||||||
The vote required to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending March 31, 2027 was the affirmative vote of a majority of the votes cast on the proposal. Accordingly, the Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending March 31, 2027.
For more information about each of the foregoing proposals, please review the Company's definitive proxy statement, filed with the SEC on July 31, 2026.
VistaGen Therapeutics Inc. published this content on September 11, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 11, 2026 at 10:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]